Impact of Von Willebrand Factor and Its Multimers on Angiogenesis

Von Willebrand Diseases Clinical Trial

— WILLANGIO  

Official title:

Impact of Von Willebrand Factor and Its Multimers on Angiogenesis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04810702
• Other study ID #: RC20_0531
• Status: Recruiting
• Start date: February 7, 2024
• Est. completion date: August 7, 2024

Study information

• Verified date: March 2024
• Source: Nantes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study aims to study the expression of numerous proteins involved in angiogenesis in 70 patients with von Willebrand disease in order to try to identify markers of interest. Secondly, the investigators plan to investigate whether there is a relationship between the proteins tested, the distribution of multimers and the clinical phenotype of the patients, in particular by looking for the presence of bleeding linked to the presence of angiodysplasias.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: August 7, 2024
• Est. primary completion date: August 7, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

For patients:

• Patient with von Willebrand disease proven by genetic analysis of the VWF gene.

• Lack of treatment that could interfere with angiogenesis.

• Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.

For the control:

• Patient with a normal coagulation report

• Absence of abnormal hemorrhagic symptoms

• Lack of notion of angiodysplasia.

• Lack of treatment that could interfere with angiogenesis.

• Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.

Exclusion Criteria:

• Patient under guardianship or curatorship.

• Pregnant and lactating women.

• Blood transfusion or treatment with von Willebrand factor concentrates less than 7 days old.

• Treatment which may interfere with angiogenesis.

Related Conditions & MeSH terms

• Von Willebrand Diseases

Intervention

Other:
• no intervention
no intervention

Locations

Country	Name	City	State
France	CHU de Nantes	Nantes

Sponsors (1)

Lead Sponsor	Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To study the relationship between proteins involved in angiogenesis and the distribution of multimers in patients with von Willebrand disease in order to define markers of interest	Compare the distribution of multimers assays between different groups of patients and the control group	1 year
Primary	To study the relationship between proteins involved in angiogenesis and the distribution of multimers in patients with von Willebrand disease in order to define markers of interest	Compare the distribution of protein assays between different groups of patients and the control group	1 year
Secondary	To study the relationship between the distribution of multimers and the clinical phenotype of patients, and in particular the presence of angiodysplasias	To study the correlation between the clinical phenotype and the assays of angiogenesis proteins	1 year
Secondary	To study the relationship between the markers of interest and the clinical phenotype of patients, and in particular the presence of angiodysplasias	To study the correlation between the clinical phenotype and the distribution of multimers	1 year